SCHEMBL12378831

SCHEMBL12378831

Cc1cc(-c2oc3cc(O)cc(O)c3c(=O)c2O)ccc1O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.78
KMT2A Q03164 9/20 0.78
CYP1A2 P05177 8/20 0.78
CYP1A1 P04798 7/20 0.78
CYP1B1 Q16678 7/20 0.78
CYP3A4 P08684 7/20 0.78
ABCB1 P08183 7/20 0.78
CYP2C9 P11712 6/20 0.78
XDH P47989 6/20 0.78
KDM4E B2RXH2 6/20 0.78
HSD17B10 Q99714 6/20 0.78
FTO Q9C0B1 6/20 0.78
MAPT P10636 6/20 0.78
APP P05067 6/20 0.78
ALOX15 P16050 5/20 0.78
IPMK Q8NFU5 5/20 0.78
IP6K2 Q9UHH9 5/20 0.78
RECQL P46063 5/20 0.78
TDP1 Q9NUW8 5/20 0.78
HIF1A Q16665 4/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12378872 0.92 MEN1 (0.73) MEN1KMT2ACYP1A2CYP1A1CYP1B1
SCHEMBL9288825 0.89 MEN1 (0.78) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL27746111 0.88 MEN1 (0.94) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL29353785 0.87 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL31507620 0.87 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL17629824 0.87 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL29351036 0.87 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL29723041 0.87 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL19723 0.87 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Quercetin SCHEMBL118425 0.87 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11872236-B2 Pharmacological agents for treating ocular diseases CALASIA PHARMACEUTICALS, INC. (US) 2024-01-16 US disclosed
US-20230255920-A1 METHOD FOR TREATING METASTATIC PROSTATE CANCER THE WILLIAM M YARBROUGH FOUNDATION 2023-08-17 US disclosed
US-20230200388-A1 COMPOUNDS AND METHODS FOR STIMULATING PLANTS Sound Agriculture Company (US) 2023-06-29 US disclosed
EP-2948437-B1 APPROACH FOR SYNTHESIS OF CATECHINS EPIRIUM BIO INC (US) 2021-11-03 EP disclosed
US-9458483-B2 Compositions comprising a polypeptide having cellulolytic enhancing activity and a bicyclic compound and uses thereof NOVOZYMES, INC. (US) 2016-10-04 US disclosed
US-20150307908-A1 Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Bicyclic Compound And Uses Thereof UNITED STATES DEPARTMENT OF ENERGY 2015-10-29 US disclosed
US-9057086-B2 Compositions comprising a polypeptide having cellulolytic enhancing activity and a bicycle compound and uses thereof NOVOZYMES, INC. (US) 2015-06-16 US disclosed
US-8865779-B2 Compounds, compositions, and methods for reducing or eliminating bitter taste CHROMOCELL CORPORATION (US) 2014-10-21 US disclosed
US-20130217077-A1 Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Bicyclic Compound And Uses Thereof NOVOZYMES, INC. (US) 2013-08-22 US disclosed
US-20110190514-A1 PYRONE ANALOG COMPOSITIONS AND METHODS LIMERICK BIOPHARMA, INC. (US) 2011-08-04 US disclosed
EP-2060251-B1 Method for manufacturing active agent concentrates COGNIS IP MAN GMBH (DE) 2011-03-23 EP disclosed
US-20080279794-A1 Use of halogenated hydroxydiphenyl ether compounds for the treatment of the skin BASCHONG WERNER 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11872236-B2 Pharmacological agents for treating ocular diseases CRYAA, CRYAB, TTR MEN1 3695/4885KMT2A 4785/4885CYP1A2 3739/4885
US-20230200388-A1 COMPOUNDS AND METHODS FOR STIMULATING PLANTS SNRK, GRK1, PPIP5K2 MEN1 3498/4885KMT2A 3582/4885CYP1A2 4273/4885
US-20110190514-A1 PYRONE ANALOG COMPOSITIONS AND METHODS CYP11B2, CYP11B1, GLS2 MEN1 535/4885KMT2A 4673/4885CYP1A2 817/4885
US-20080279794-A1 Use of halogenated hydroxydiphenyl ether compounds for the treatment of the skin MC1R, TYR, MC3R MEN1 659/4885KMT2A 2258/4885CYP1A2 77/4885
US-20230255920-A1 METHOD FOR TREATING METASTATIC PROSTATE CANCER BPHL, KLK3, ACP3 MEN1 968/4885KMT2A 378/4885CYP1A2 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.